AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook

Go back to AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook

Credit Suisse Downgrades Abbvie (ABBV) to Neutral; Path to Upside Difficult

October 31, 2016 7:13 AM EDT

Credit Suisse downgraded Abbvie (NYSE: ABBV) from Outperform to Neutral with a price target of $60.00 (from $70.00), saying while valuation may be compelling the path to upside is difficult.

Analyst Vamil Divan commented, "We downgrade ABBV shares to Neutral and lower our target price to $60 (from... More

AbbVie (ABBV) Raises Quarterly Dividend 12.3% to $0.64; 4.2% Yield

October 28, 2016 7:45 AM EDT

AbbVie (NYSE: ABBV) declared a quarterly dividend of $0.64 per share, or $2.56 annualized. This is a 12.3% increase from the prior dividend of $0.57.

The dividend will be payable on February 15, 2017, to stockholders of record on January 13, 2017, with an ex-dividend date of January 11,... More